Prelude Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-259,762
| Closed | -$4.67M | – | 2617 |
|
|
2020
Q2 | $4.67M | Buy |
+259,762
| New | +$3.61M | 0.26% | 56 |
|
|
2019
Q3 | – | Sell |
-34,328
| Closed | -$931K | – | 2245 |
|
|
2019
Q2 | $931K | Buy |
34,328
+10,978
| +47% | +$344K | 0.05% | 359 |
|
|
2019
Q1 | $810K | Buy |
+23,350
| New | +$674K | 0.05% | 379 |
|
|
2018
Q4 | – | Sell |
-113,350
| Closed | -$3.02M | – | 2330 |
|
|
2018
Q3 | $3.02M | Buy |
113,350
+68,978
| +155% | +$2.25M | 0.18% | 102 |
|
|
2018
Q2 | $1.68M | Buy |
+44,372
| New | +$1.7M | 0.11% | 204 |
|
|
2018
Q1 | – | Sell |
-187
| Closed | -$9K | – | 1824 |
|
|
2017
Q4 | $9K | Sell |
187
-3
| -2% | -$152 | ﹤0.01% | 1224 |
|
|
2017
Q3 | $10K | Sell |
190
-57
| -23% | -$3.35K | ﹤0.01% | 1440 |
|
|
2017
Q2 | $14K | Sell |
247
-853
| -78% | -$34.2K | ﹤0.01% | 1342 |
|
|
2017
Q1 | $43K | Buy |
+1,100
| New | +$35K | ﹤0.01% | 1071 |
|
|
2015
Q1 | – | Sell |
-4,400
| Closed | -$125K | – | 2302 |
|
|
2014
Q4 | $125K | Buy |
+4,400
| New | +$122K | 0.02% | 918 |
|
Prelude Capital Management's PTLA Position: Q3 2020 in Review
Prelude Capital Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 259,762 shares — an estimated $4.67M sold.
Prelude Capital Management first reported a position in PTLA in Q4 2014 and held it in 10 quarters. The position peaked at $4.67M in Q2 2020. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Prelude Capital Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Prelude Capital Management sold 259,762 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $4.67M.
- Prelude Capital Management first reported a position in Portola Pharmaceuticals, Inc. in Q4 2014 and held it in 10 quarters.
- Prelude Capital Management's Portola Pharmaceuticals, Inc. position peaked at $4.67M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Prelude Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.